| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Service de Neurologic (Prof. Confavreux and Drs. Grimaud and Moreau), Hopital de l'Antiquaille, Lyon, France; the Department of Epidemiology (Dr. Saddier), UNC, Chapel Hill, NC; the Laboratoire d'Informatique Medicale (Prof. Adeleine), Hospices Civils de Lyon, Lyon; and the Clinique de Neurologie (Prof. Aimard), Hopital Neurologique, Lyon, France.
Supported by funds from the Hospices Civils de Lyon and by grants from the Commission of the European Communities DG XII (contract no. BMH1-CT93-1529), the Ligue Francaise Contre la Sclerose En Plaques, and the Nouvelle Association Francaise des Scleroses en Plaques.
Received September 6, 1995. Accepted in final form November 16, 1995.
Address correspondence and reprint requests to Prof. C. Confavreux, Service de Neurologie, Hopital de l'Antiquaille, 1 rue de l'Antiquaille, 69321 Lyon Cedex 05, France.
An increased risk of cancer has been reported in patients treated with azathioprine.To assess the long-term risk of neoplasia in azathioprine-treated multiple sclerosis (MS) patients, we conducted a case-control study using the Lyon Multiple Sclerosis Database. From the 1,191 MS patients included in the database, we identified patients who developed cancer before December 31, 1991. Each case was then matched to three cancer-free MS controls by gender, date of birth, and date of MS onset. A matched analysis was performed to compare cases and controls for exposure to azathioprine therapy during the same follow-up period. Twenty-three MS patients with cancer were identified: 17 solid tumors, 2 skin carcinomas, 4 hematopoietic cancers. Cases had a mean age of 34.5 years +/- 10.2 (+/-SD) at clinical onset of MS and have been followed up for an average 13.8 years +/- 8.1 before being diagnosed with cancer. Fourteen cases (61%) and 34 controls (49%) had been treated with azathioprine for at least 1 month after being diagnosed with MS (adjusted odds ratio = 1.7; 95% confidence interval [CI], 0.6 to 4.6). When assessing risk associated with different durations of azathioprine therapy compared with no treatment at all, we found that MS patients had an increase in cancer risk of 1.3 (95% CI, 0.4 to 4.0) when treated less than 5 years, of 2.0 (95% CI, 0.4 to 9.1) when treated 5 to 10 years, and of 4.4 (95% CI, 0.9 to 20.9) when treated more than 10 years. Similar results were obtained when assessing cancer risk associated with cumulative doses of azathioprine ever taken. This case-control study suggests that the overall long-term risk of cancer from azathioprine is low in MS patients. The results are suggestive of a dose-response relationship with no significant risk during the first years of treatment and a possible increased risk after about 10 years of continuous therapy. Further studies are needed to better assess the risk-benefit ratio of azathioprine in MS.
NEUROLOGY 1996;46: 1607-1612
This article has been cited by other articles:
|
|
 |
|
  S. Bahmanyar, S. M. Montgomery, J. Hillert, A. Ekbom, and T. Olsson Cancer risk among patients with multiple sclerosis and their parents Neurology, March 31, 2009; 72(13): 1170 - 1177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Casetta, G Iuliano, and G Filippini Azathioprine for multiple sclerosis J. Neurol. Neurosurg. Psychiatry, February 1, 2009; 80(2): 131 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lebrun, M. Debouverie, P. Vermersch, P. Clavelou, L. Rumbach, J. de Seze, S. Wiertlevski, G. Defer, O. Gout, F. Berthier, et al. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis Multiple Sclerosis, April 1, 2008; 14(3): 399 - 405. [Abstract] [PDF]
|
|
|
|
|
|
H Butzkueven, J Chapman, E Cristiano, F Grand'Maison, M Hoffmann, G Izquierdo, D Jolley, L Kappos, T Leist, D Pohlau, et al. MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis Multiple Sclerosis, November 1, 2006; 12(6): 769 - 774. [Abstract] [PDF]
|
|
|
|
|
|
N. Putzki, S. Knipp, T i. Ramczykowski, S. Vago, U. Germing, H. Chr. Diener, and V. Limmroth Secondary myelodysplastic syndrome following long-term treatment with azathioprine in patients with multiple sclerosis Multiple Sclerosis, June 1, 2006; 12(3): 363 - 366. [Abstract] [PDF]
|
|
|
|
|
|
S L Minden, D Frankel, L Hadden, J Perloff, K P Srinath, and D C Hoaglin The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics Multiple Sclerosis, February 1, 2006; 12(1): 24 - 38. [Abstract] [PDF]
|
|
|
|
 |
|
 M. J. Kothari Myasthenia Gravis J Am Osteopath Assoc, September 1, 2004; 104(9): 377 - 384. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E Portaccio, V Zipoli, G Siracusa, S Piacentini, S Sorbi, and M P Amato Safety and tolerability of cyclophosphamide 'pulses' in multiple sclerosis: a prospective study in a clinical cohort Multiple Sclerosis, October 1, 2003; 9(5): 446 - 450. [Abstract] [PDF]
|
|
|
|
 |
|
 C. L M Sudlow and C. E Counsell Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis BMJ, February 15, 2003; 326(7385): 388 - 392. [Full Text] [PDF]
|
|
|
|
|
|
R G Ghalie, E Mauch, G Edan, H P Hartung, R E Gonsette, S Eisenmann, E Le Page, M D Butine, and D E Goodkin A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis Multiple Sclerosis, October 1, 2002; 8(5): 441 - 445. [Abstract] [PDF]
|
|
|
|
 |
|
 J. N. Pruitt II and T. R. Swift Therapies for Disorders of the Neuromuscular Junction Arch Neurol, May 1, 2002; 59(5): 739 - 742. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Confavreux, S. Suissa, P. Saddier, V. Bourdes, S. Vukusic, and The Vaccines in Multiple Sclerosis Study Group Vaccinations and the Risk of Relapse in Multiple Sclerosis N. Engl. J. Med., February 1, 2001; 344(5): 319 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. F Smith and C. L Darlington Recent developments in drug therapy for multiple sclerosis Multiple Sclerosis, April 1, 1999; 5(2): 110 - 120. [Abstract] [PDF]
|
|
|
|
|
|
R. A. Rudick, J. A. Cohen, B. Weinstock-Guttman, R. P. Kinkel, and R. M. Ransohoff Management of Multiple Sclerosis N. Engl. J. Med., November 27, 1997; 337(22): 1604 - 1611. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
